SPECIAL EDITION
Apr i l 2014
N° 148
BIS
2015
A
Reliable, rigorously independent information
on treatments and healthcare strategies, to enable fully
informed decision-making. No grants, no advertising.
No shareholders, no sponsors.
Prescrire
is financed
by its subscribers.
How we work
Prescrire’s
complex, collective editing process has
been fine-tuned over the years
Prescrire’s
reviews, written by specially trained healthcare
professionals, are based on an exhaustive search of the
literature, and undergo scrutiny by a large panel of outside
reviewers plus rigorous quality control procedures.
All the reviews published in
Prescrire
(aside from a few clearly labelled
exceptions, such as readers’ letters)
are written by Prescrire’s Editorial Staff.
Prescrire
does not publish unsolicited
manuscripts from outside contributors.
The production of reviews draws
upon a wide range of skills, all exer-
cised under the supervision of
Prescrire
’
s
Editor. This team approach is reflected
in the collective byline “©Prescrire”.
Written and edited by
healthcare professionals
Prescrire’s
editors are physicians
(both general practitioners and special-
ists, in individual practice or on hospital
staff), pharmacists (working in pharma-
cies or hospitals), nurses and dentists.
A few are economists or journalists with
specific expertise in the area of health-
care. All
Prescrire
editors have received
extensive in-house training in
Prescrire’s
editorial production process.
Editors free from conflicts
of interest
The absence of any direct or indirect
financial links to the pharmaceutical
industry is an absolute requirement to
be a member of the Prescrire team. Any
such link is cause for dismissal from the
Prescrire Editorial Staff.
A vast network
of reviewers
Once they are in an advanced stage
of editing and quality control, all draft
reviews are sent to outside reviewers
(10 to 40 reviewers read each draft at
this stage).
These reviewers critique each article
in terms of content, style, relevance,
newsworthiness, presentation of argu-
ments and usefulness in daily practice.
The reviewers are specialists in the sub-
ject being discussed, methodologists,
or healthcare professionals representa-
tive of
Prescrire’s
readers (and chosen
from their midst).
Editorial
Repeating the same mistake
..........
p. 2
EMA approval of a second course of
varenicline
for smoking cessation is
unfortunate
New Products
Rivaroxaban 2.5 mg (Xarelto°)
........
p. 3
No justification for using this anticoagulant
after an acute coronary syndrome
Aflibercept (Eylea°) and central
retinal vein occlusion
.......................
p. 4
No proven advantages but many
uncertainties
Sofosbuvir (Sovaldi°)
.........................
p. 5
Active against hepatitis C virus, but
evaluation is incomplete
Imanitib (Glivec°)
...............................
p. 6
Prolonged survival in Philadelphia
chromosome-positive cases
Strontium (Protelos°)
........................
p. 7
Still authorised despite an unfavourable
opinion of the European pharmacovigilance
committee
Adverse Effects
Choosing not to
take bromocriptine
...........................
p. 8
Results of a survey in a maternity clinic
Pregabalin :
major weight gain
.............................
p. 8
Up to 20 kg
Lamotrigine: nightmares
.................
p. 9
Dose-dependent
Pazopanib:
retinal detachment
...........................
p. 9
Patient sould be informed
Cefepime: serious neurological
adverse effects
..................................
p. 9
Renal impairment is a risk factor
Reviews
Prevention of migraine attacks
.....
p. 10
First-choice treatments
Outlook
Dare to refuse the exorbitant price
of Sovaldi° !
.......................................
p. 12
Blatant profiteering
Prescrire International Special Edition 2015/Volume 24 N°158
A
•
P
age
1
C O N T E N T S
